<code id='726D1DE115'></code><style id='726D1DE115'></style>
    • <acronym id='726D1DE115'></acronym>
      <center id='726D1DE115'><center id='726D1DE115'><tfoot id='726D1DE115'></tfoot></center><abbr id='726D1DE115'><dir id='726D1DE115'><tfoot id='726D1DE115'></tfoot><noframes id='726D1DE115'>

    • <optgroup id='726D1DE115'><strike id='726D1DE115'><sup id='726D1DE115'></sup></strike><code id='726D1DE115'></code></optgroup>
        1. <b id='726D1DE115'><label id='726D1DE115'><select id='726D1DE115'><dt id='726D1DE115'><span id='726D1DE115'></span></dt></select></label></b><u id='726D1DE115'></u>
          <i id='726D1DE115'><strike id='726D1DE115'><tt id='726D1DE115'><pre id='726D1DE115'></pre></tt></strike></i>

          explore

          explore

          author:Wikipedia    Page View:656
          An light blue number 3 with an eye is surrounded by smaller, black number 3s on an orange background — 3 to watch coverage from STAT
          Christine Kao/STAT

          It’s been a slow year for medtech. Major deals in 2023 were scarce, funding was hard to come by, and valuations were down. On the policy side, the industry grappled with changing AI regulations, reimbursement woes, and device sterilization rules.

          Here are three political and market forces that shaped the medtech industry last year, and are worth paying attention to in 2024:

          advertisement

          Lobbying power of AI, software-enabled devices

          Medtech lobby AdvaMed announced earlier this month that the major medical imaging companies, previously housed within the National Electrical Manufacturers Association, were shifting to their shop. The device group also created a separate niche for digital health companies in October.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          STAT Summit: How researchers deal with rejection
          STAT Summit: How researchers deal with rejection

          Fromlefttoright:BrendaCabrera-Mendoza,LaurenGhazal,andZhiYuatthe2023STATSummit.STATAttheageof26,Laur

          read more
          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more

          Roivant's CEO is a star, but biotech's black hole persists

          MollyFerguson/STATRoivantSciences’MattGlinemightbethisyear’sbestbiopharmaCEO,andotherthoughtsaboutMo